Evangelos Triantafyllou is Lecturer in Liver Immunology in the Section of Hepatology and Gastroenterology. He received his BSc Biology from the National and Kapodistrian University of Athens in 2011, and his MSc Developmental Biology from the University of Bath in 2012. He then continued to undertake a PhD in Liver Immunology at King’s College London (Institute of Liver Studies, 2013-2017) investigating the mechanisms of immune-mediated injury in liver failure, spending a part of his doctoral work at the University of Birmingham (Centre for Liver and Gastrointestinal Research, 2013-2015). In 2017 he joined Imperial College to conduct his post-doctoral research, receiving funding from the Rosetrees Trust, UKRI MRC, and an Imperial College Research Fellowship award. Evangelos investigates the dysregulated immune responses during acute and chronic liver injury, with special interest on the inflammatory and bactericidal functions of blood and liver myeloid cells.
Liver Immunology Group:
The Liver Immunology Group is located on the Hammersmith (Commonwealth Building, 10th floor) and St Mary’s (QEQM Building, 10th floor) campuses. Our laboratory includes a close collaboration between scientists and clinicians, and conducts basic, translational, and clinical research. We investigate the cellular, molecular, and metabolic crosstalk underlying immune dysregulation during acute (e.g., paracetamol overdose) and chronic (e.g., fibrosis, cirrhosis) liver injury. To explore this, we study both human tissue samples and in vivo models of liver injury using a range of advanced technological tools (e.g., liver intravital imaging, tissue multiplex staining, single-cell RNA seq, metabolomics). Our research aims to improve our immunological understanding of liver disease pathogenesis and identify targets for developing new immunomodulatory therapeutic approaches.
- Immunomodulatory therapeutic approaches in liver disease
- Checkpoint pathways [e.g., PD-(L)1, TIGIT axis] and immune dysregulation during - acute and chronic liver injury
- Immune cell crosstalk in checkpoint inhibitor-related hepatitis
- Dysregulated immunometabolism in liver failure syndromes
- TAM (Tyro3, Axl, MerTK) receptors and macrophage biology in chronic liver disease
- Gut microbiota and immune landscape in non-alcoholic fatty liver disease
Funding: UKRI Medical Research Council, Rosetrees Trust
et al., 2022, Lipids in liver failure syndromes: a focus on eicosanoids, specialized pro-resolvinglipid mediators and lysophospholipids., Frontiers in Immunology, Vol:13, ISSN:1664-3224, Pages:1-21
Singanayagam A, Triantafyllou E, 2021, Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting, Frontiers in Immunology, Vol:12
et al., 2021, PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury, Journal of Clinical Investigation, Vol:131, ISSN:0021-9738
et al., 2018, The role of monocytes and macrophages in acute and acute-on-chronic liver failure, Frontiers in Immunology, Vol:9, ISSN:1664-3224
et al., 2017, MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure, Gut, Vol:67, ISSN:1468-3288, Pages:333-347